Skip to main content
. 2021 Sep 21;207:67–74. doi: 10.1016/j.thromres.2021.09.009

Table 2.

Characteristics of patients hospitalized for VT and PE, and of the related hospital stay between January (Week 1) and October (Week 40) 2020 compared with the corresponding time period in 2017–2019, according to the type of diagnosis. Bold: p-value < 0.05.


Deep venous thrombosis as primary diagnosis
Pulmonary embolism as primary diagnosis
Deep venous thrombosis as associated diagnosis
Pulmonary embolism as associated diagnosis
Year 2017–2019 2020 p 2017–2019 2020 p 2017–2019 2020 p 2017–2019 2020 p
Patients' characteristics
Women, % 52.8 52.4 0.50 52.6 52.0 0.05 48.2 46.6 <0.01 50.6 47.3 <0.01
Age, mean (std) 65.6 (19.4) 64.7 (19.9) <0.01 69.0 (16.8) 68.5 (17.2) <0.01 67.0 (18.8) 66.9 (18.6) 0.18 70.3 (16.0) 69.4 (16.1) <0.01
0–65 years old, % 41.6 42.9 0.03 33.9 35.1 <0.01 38.0 37.9 0.79 31.1 33.6 <0.01
Charlson index score, % 0.02 <0.01 <0.01 <0.01
 • 0–1 42.5 43.5 49.8 50.5 38.1 38.2 35.2 41.5
 • 2–3 27.6 26.2 27.5 27.7 31.9 32.4 33.9 31.6
 • 4+ 29.9 30.3 22.7 21.8 30.0 29.4 30.8 26.9
Hospitalization or official ‘long-term disease’ status in the five years preceding the index hospitalizationa
 • Pulmonary embolism 3.6 2.7 <0.01 10.0 9.3 <0.01 2.6 1.7 <0.01 13.4 9.6 <0.01
 • Venous thromboembolism 16.9 17.8 0.04 12.2 10.9 <0.01 11.4 9.8 <0.01 16.0 11.4 <0.01
 • Coagulation abnormalities 9.8 10.1 0.42 6.2 6.3 0.52 7.8 7.6 0.07 6.4 5.3 <0.01
 • Stroke 5.8 5.9 0.52 5.6 5.7 0.36 8.1 8.4 0.03 9.7 9.4 0.36
 • Ischemic heart disease 15.5 14.8 0.08 12.9 12.2 <0.01 16.8 17.2 0.06 15.4 14.1 <0.01
 • Heart failure 13.7 13.2 0.21 14.0 13.4 0.01 15.4 15.6 0.13 16.6 14.2 <0.01
Treatment delivery in the year preceding the index hospitalizationa
 • Antihypertensives 53.8 52.6 0.03 53.7 51.1 <0.01 57.3 57.3 0.77 58.1 54.9 <0.01
 • Antidiabetics 15.7 16.2 0.27 12.0 11.9 0.69 17.6 18.7 <0.01 15.6 16.0 0.20
 • Lipid-lowering medications 26.7 25.2 <0.01 27.0 24.4 <0.01 27.7 27.9 0.20 28.4 26.6 <0.01
 • Oral anticoagulants 11.0 10.5 0.15 7.3 5.9 <0.01 14.9 14.7 0.16 14.8 11.1 <0.01
 • Heparin 5.6 4.7 <0.01 2.6 2.1 <0.01 6.2 4.8 <0.01 5.2 3.5 <0.01
 • Antiplatelets 24.5 23.2 <0.01 22.3 20.9 <0.01 25.1 25.1 0.96 24.2 23.0 <0.01



Disease management and hospital stay
Length of stay, mean (std) 7.1 (9.0) 7.2 (9.9) <0.01 9.3 (9.4) 9.0 (9.0) <0.01 16.1 (16.8) 16.5 (17.3) <0.01 17.7 (18.2) 18.0 (17.9) <0.01
Admitted to intensive care unit, %b 4.4 4.8 0.09 26.7 26.1 0.02 16.9 19.8 <0.01 23.4 28.0 <0.01
In-patient mortality, % 1.7 1.8 0.53 4.8 4.9 0.51 7.3 7.8 <0.01 15.3 16.1 <0.01
90-day post-admission mortality, %b 7.6 8.3 0.06 7.2 8.0 <0.01 12.0 11.9 0.82 15.4 15.0 0.27

std: standard deviation; p: 2020 vs. 2017–2019.

a

Available for patients without linkage error (i.e., 99% of patients).

b

Available for patients affiliated to France's general healthcare insurance scheme (i.e., 77% of included patients).